First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

Tezepelumab demonstrated rapid and sustained clinical improvements in nasal polyp burden and symptom control, with effects ...

The complete response (CR) rate at 1 month improved from 25% with single-fraction conformal 3D RT (3D-CRT) to 37% with SBRT, ...

Denmark's economic growth, which was driven by what economists described as an "exceptional surge" in pharmaceutical exports, ...

CEO Önal said Türk Telekom had a ‘spectacular’ start to the year, primarily driven by the maintained strength in fixed ...

Artificial intelligence is gaining ground in healthcare, and tech's biggest players are racing to stake their claims.

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing facility will be ...

FDA Commissioner Marty Makary said Thursday that his agency is preparing to release a new regulatory framework within the ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

Disrupting tiny droplets that switch on cancer genes may be a strategy for treating a rare #kidneycancer known as ...

The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as ...

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...